Postes actifs de Joseph Wilkinson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | President | 07/12/2023 | - |
Directeur des opérations | 07/12/2023 | - | |
Directeur/Membre du Conseil | - | 07/12/2023 |
Historique de carrière de Joseph Wilkinson
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Chief Operating Officer | 1 |
President | 1 |
Sectorielle
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | Commercial Services |
- Bourse
- Insiders
- Joseph Wilkinson
- Expérience